HCA Healthcare (NYSE:HCA) Receives “Overweight” Rating from Cantor Fitzgerald

HCA Healthcare (NYSE:HCA)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They presently have a $335.00 target price on the stock. Cantor Fitzgerald’s price target points to a potential upside of 2.66% from the stock’s previous close.

Several other research analysts also recently weighed in on HCA. Deutsche Bank Aktiengesellschaft lifted their target price on HCA Healthcare from $359.00 to $375.00 and gave the company a “buy” rating in a research note on Friday, June 28th. JPMorgan Chase & Co. lifted their price target on HCA Healthcare from $327.00 to $332.00 and gave the company a “neutral” rating in a research note on Thursday, May 30th. Barclays lifted their price target on HCA Healthcare from $356.00 to $367.00 and gave the company an “overweight” rating in a research note on Monday, April 29th. Baird R W upgraded HCA Healthcare to a “strong-buy” rating in a research note on Thursday, May 30th. Finally, Robert W. Baird started coverage on HCA Healthcare in a report on Thursday, May 30th. They set an “outperform” rating and a $396.00 price objective for the company. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $326.53.

HCA Healthcare Trading Up 2.1 %

NYSE:HCA opened at $326.31 on Tuesday. The stock’s 50 day moving average price is $326.06 and its 200 day moving average price is $318.07. The company has a market capitalization of $85.46 billion, a PE ratio of 16.28, a P/E/G ratio of 1.49 and a beta of 1.68. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 29.26. HCA Healthcare has a 52-week low of $215.96 and a 52-week high of $344.20.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, April 26th. The company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.35. HCA Healthcare had a return on equity of 674.49% and a net margin of 8.20%. The firm had revenue of $17.34 billion for the quarter, compared to the consensus estimate of $16.81 billion. During the same quarter last year, the business posted $4.93 EPS. The firm’s quarterly revenue was up 11.2% compared to the same quarter last year. On average, research analysts anticipate that HCA Healthcare will post 20.92 EPS for the current year.

Insider Activity at HCA Healthcare

In related news, SVP Kathryn A. Torres sold 1,863 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $326.18, for a total value of $607,673.34. Following the completion of the transaction, the senior vice president now directly owns 19,612 shares in the company, valued at $6,397,042.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other HCA Healthcare news, SVP Kathryn A. Torres sold 1,863 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $326.18, for a total transaction of $607,673.34. Following the completion of the sale, the senior vice president now owns 19,612 shares of the company’s stock, valued at $6,397,042.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael S. Cuffe sold 1,600 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $309.00, for a total value of $494,400.00. Following the sale, the executive vice president now directly owns 34,124 shares of the company’s stock, valued at approximately $10,544,316. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,397 shares of company stock worth $3,921,929. 1.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On HCA Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of HCA Healthcare by 0.4% in the first quarter. Vanguard Group Inc. now owns 16,989,683 shares of the company’s stock worth $5,666,569,000 after buying an additional 60,304 shares during the period. Sanders Capital LLC boosted its position in shares of HCA Healthcare by 4.2% in the fourth quarter. Sanders Capital LLC now owns 11,404,003 shares of the company’s stock worth $3,086,836,000 after buying an additional 456,738 shares during the period. Wellington Management Group LLP boosted its position in shares of HCA Healthcare by 1.7% in the fourth quarter. Wellington Management Group LLP now owns 10,186,129 shares of the company’s stock worth $2,757,181,000 after buying an additional 170,560 shares during the period. Royal Bank of Canada boosted its position in shares of HCA Healthcare by 35.7% in the fourth quarter. Royal Bank of Canada now owns 4,503,918 shares of the company’s stock worth $1,219,121,000 after buying an additional 1,183,890 shares during the period. Finally, Capital World Investors lifted its stake in shares of HCA Healthcare by 57.5% in the first quarter. Capital World Investors now owns 2,792,377 shares of the company’s stock worth $931,342,000 after acquiring an additional 1,019,750 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.